The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cystic fibrosis in the year 2020: A disease with a new face
Abstract
The autosomal recessive disease cystic fibrosis (CF) was once untreatable and deadly in childhood, but now most patients survive to adulthood. Many countries have instituted CF newborn screening because early diagnosis improves outcome. CF research has greatly intensified following the discovery of the CF transmembrane conductance regulator (CFTR) gene, which has more than 2000 different mutations. For patients with common mutations like F508del, CFTR modulators are life transforming and may even prevent major complications if started early in childhood. For some patients with rare CFTR mutations, a treatment path still needs to be developed. Conclusion: This review provides a general update on CF, including screening and current and future treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Self-citationHeijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32597-8 · Cited by 1,414
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999
ECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Sass, L. A., Tullis, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807120 · Cited by 726
Veit, G., Avramescu, R. G., Chiang, A. N., Houck, S. A., Cai, Z., Peters, K. W., Hong, J. S., Pollard, H. B., Guggino, W. B., Balch, W. E., et al. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0935 · Cited by 580
Progress in therapies for cystic fibrosis
De Boeck, K., & Amaral, M. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00023-0 · Cited by 451
Self-citationKerem, B. S., Zielenski, J., Markiewicz, D., Bozon, D., Gazit, E., Yahav, J., Kennedy, D., Riordan, J. R., Collins, F. S., & Rommens, J. M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8447 · Cited by 421
Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study
McKone, E. F., Emerson, S. S., Edwards, K. L., & Aitken, M. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13368-5 · Cited by 397
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
De Boeck, K., Munck, A., Walker, S., Faro, A., Hiatt, P., Gilmartin, G., & Higgins, M. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.09.005 · Cited by 394
Self-citationCystic fibrosis: impaired bicarbonate secretion and mucoviscidosis
Quinton, P. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61162-9 · Cited by 381
Davies, J. C., Cunningham, S., Harris, W. T., Lapey, A., Regelmann, W. E., Sawicki, G. S., Southern, K. W., Robertson, S., Green, Y., Cooke, J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00545-7 · Cited by 347
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Davies, J. C., Moskowitz, S. M., Brown, C., Horsley, A., Mall, M. A., McKone, E. F., Plant, B. J., Prais, D., Ramsey, B. W., Taylor-Cousar, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807119 · Cited by 331
Factors associated with FEV1decline in cystic fibrosis: analysis of the ECFS Patient Registry
Kerem, E., Viviani, L., Zolin, A., MacNeill, S., Hatziagorou, E., Ellemunter, H., Drevinek, P., Gulmans, V., Krivec, U., & Olesen, H. (2014) · European Respiratory Journal · doi:10.1183/09031936.00166412 · Cited by 296
Airway acidification initiates host defense abnormalities in cystic fibrosis mice
Shah, V. S., Meyerholz, D. K., Tang, X. X., Reznikov, L., Abou Alaiwa, M., Ernst, S. E., Karp, P. H., Wohlford-Lenane, C. L., Heilmann, K. P., Leidinger, M. R., et al. (2016) · Science · doi:10.1126/science.aad5589 · Cited by 291
Mott, L. S., Park, J., Murray, C. P., Gangell, C. L., de Klerk, N. H., Robinson, P. J., Robertson, C. F., Ranganathan, S. C., Sly, P. D., Stick, S. M., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-200912 · Cited by 278
Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., Davies, J. C., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30202-9 · Cited by 273
An overview of the pathogenesis of cystic fibrosis lung disease
Boucher, R. C. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00144-8 · Cited by 254
Moss, R. B., Flume, P. A., Elborn, J. S., Cooke, J., Rowe, S. M., McColley, S. A., Rubenstein, R. C., & Higgins, M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00201-5 · Cited by 228
The relative frequency of CFTR mutation classes in European patients with cystic fibrosis
De Boeck, K., Zolin, A., Cuppens, H., Olesen, H. V., & Viviani, L. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.12.003 · Cited by 224
Self-citationBessonova, L., Volkova, N., Higgins, M., Bengtsson, L., Tian, S., Simard, C., Konstan, M. W., Sawicki, G. S., Sewall, A., Nyangoma, S., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210394 · Cited by 214
Effect of Estrogen on Pseudomonas Mucoidy and Exacerbations in Cystic Fibrosis
Chotirmall, S. H., Smith, S. G., Gunaratnam, C., Cosgrove, S., Dimitrov, B. D., O'Neill, S. J., Harvey, B. J., Greene, C. M., & McElvaney, N. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106126 · Cited by 211
Newborn screening for cystic fibrosis
Castellani, C., Massie, J., Sontag, M., & Southern, K. W. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00053-9 · Cited by 162
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
Alton, E. W. F. W., Beekman, J. M., Boyd, A. C., Brand, J., Carlon, M. S., Connolly, M. M., Chan, M., Conlon, S., Davidson, H. E., Davies, J. C., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208406 · Cited by 150
Cystic Fibrosis Diagnosed After 2 Months of Age Leads to Worse Outcomes and Requires More Therapy
Sims, E. J., Clark, A., McCormick, J., Mehta, G., Connett, G. J., & Mehta, A. (2007) · PEDIATRICS · doi:10.1542/peds.2006-1498 · Cited by 129
Goetz, D., & Ren, C. L. (2019) · Pediatric Annals · doi:10.3928/19382359-20190327-01 · Cited by 118
The diagnosis of cystic fibrosis
Boeck, K. D., Vermeulen, F. L., & Dupont, L. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.04.010 · Cited by 117
Dijk, F. N., McKay, K., Barzi, F., Gaskin, K. J., & Fitzgerald, D. A. (2011) · Archives of Disease in Childhood · doi:10.1136/archdischild-2011-300449 · Cited by 114
Year-to-year changes in lung function in individuals with cystic fibrosis
Liou, T. G., Elkin, E. P., Pasta, D. J., Jacobs, J. R., Konstan, M. W., Morgan, W. J., & Wagener, J. S. (2010) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.04.002 · Cited by 110
Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries
Mehta, G., Maçek, M., & Mehta, A. (2010) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.08.002 · Cited by 108
Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening
Ren, C. L., Fink, A. K., Petren, K., Borowitz, D., McColley, S. A., Sanders, D. B., Rosenfeld, M., & Marshall, B. C. (2015) · PEDIATRICS · doi:10.1542/peds.2014-3698 · Cited by 90
Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing
Maule, G., Casini, A., Montagna, C., Ramalho, A. S., De Boeck, K., Debyser, Z., Carlon, M. S., Petris, G., & Cereseto, A. (2019) · Nature Communications · doi:10.1038/s41467-019-11454-9 · Cited by 86
Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients
Waters, V. J., Stanojevic, S., Sonneveld, N., Klingel, M. L., Grasemann, H., Yau, Y. C. W., Tullis, E. D., Wilcox, P., Freitag, A. P., Chilvers, M. A., et al. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.01.007 · Cited by 80
Taylor‐Cousar, J. L., Jain, M., Barto, T. L., Haddad, T., Atkinson, J. J., Tian, S., Tang, R., Marigowda, G., Waltz, D. A., & Pilewski, J. M. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.09.012 · Cited by 78
Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project
Boyle, M., Sabadosa, K. A., Quinton, H. B., Marshall, B. C., & Schechter, M. S. (2014) · BMJ Quality & Safety · doi:10.1136/bmjqs-2013-002369 · Cited by 67
Early referral to cystic fibrosis specialist centre impacts on respiratory outcome
Lebecque, P., Leonard, A., Boeck, K. D., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.07.005 · Cited by 65
Ageing in Cystic Fibrosis and Long-term Survival
Simmonds, N. J. (2013) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2013.01.007 · Cited by 47
Personalised medicine for cystic fibrosis: treating the basic defect
Elborn, J. S. (2013) · European Respiratory Review · doi:10.1183/09059180.00008112 · Cited by 45
Amaral, M. D., Boeck, K. D., Amaral, M. D., Davies, J. C., Boeck, K. D., Dřevínek, P., Elborn, J. S., Kerem, E., & Lee, T. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.06.010 · Cited by 43
Cuyx, S., & Boeck, K. D. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1696664 · Cited by 24
Scotet, V., Assael, B. M., Dugueperoux, I., et al. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.07.046 · Cited by 22
Treatment burden in patients with at least one class IV or V CFTR mutation
Dewulf, J., Vermeulen, F. L., Wanyama, S. S., Thomas, M., Proesmans, M., Dupont, L., & Boeck, K. D. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23313 · Cited by 13
Flume, P. A., Sawicki, G. S., Pressler, T., Schwarz, C., Fajac, I., Layish, D. T., Bialek, P., Wilson, S., Kang, L., McLaughlin, B., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(18)30120-6 · Cited by 11
Cited by
Minhas, S., Bettocchi, C., Boeri, L., Capogrosso, P., Carvalho, J., Cilesiz, N. C., Cocci, A., Corona, G., Dimitropoulos, K., Gül, M., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.08.014 · Cited by 622
Eisenberg, M. L., Esteves, S. C., Lamb, D. J., Hotaling, J. M., Giwercman, A., Hwang, K., & Cheng, Y.-S. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00459-w · Cited by 536
Scotet, V., L’Hostis, C., & Férec, C. (2020) · Genes · doi:10.3390/genes11060589 · Cited by 317
Metadata
- Authors
- De Boeck, K.
- Venue
- Acta Paediatrica
- Publisher
- Wiley
- Published
- 2020-01-22
- Volume
- 109
- Issue
- 5
- Pages
- 893-899
- ISSN
- 0365-1436 (ISSN-L)
- 0803-5253
- 1651-2227
- OpenAlex
- W2997272985
- Cited by
- 332
- References
- 45
- FWCI
- 26.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.